MIN-102 is an orally bioavailable selective PPAR gamma agonist that is one of the metabolites of pioglitazone and has been shown to have improved access to the central nervous system and a better safety profile. In phase 1 clinical study MIN-102 was well tolerated and it was confirmed that the compound is able to cross the blood-brain barrier and engage PPAR gamma within the CNS at an equivalent level as in preclinical studies. Such a level of PPAR gamma engagement in the CNS is well above what can be achieved with pioglitazone in humans. MIN-102 is already being tested in another rare, CNS disease, adrenomyeloneuropathy.
Voices of Friedreich's Ataxia (FA)
We Have the Power to Overcome Anything, Together!